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Abstract
Nucleotide sequences of genes conferring isoniazid resistance
(katG, inhA, oxyR–ahpC and ndh) and ethionamide resistance
(ethA) in 160 drug-resistant Mycobacterium tuberculosis clinical iso-
lates from Thailand were analysed. Mutations in the katG gene
were found in 129 isolates, predominantly at codon 315, which
was mutated in 127 isolates. Twenty-two isolates had mutations
in the inhA promoter and coding region. Mutations in the oxyR–
ahpC intergenic region and in ndh were detected in four and
one isolate(s), respectively. Of 24 ethionamide-resistant isolates,
13 had mutations in the ethA gene. However, these mutations
were dispersed along the entire gene, with no codon predomi-
nating significantly.
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Phenotypic methods of antituberculous drug susceptibility
testing are time-consuming, requiring at least 7–10 days using
automated culture systems and up to 6 weeks by
conventional methods. Much effort has been spent on
reducing the time needed to identify drug-resistant strains.
Several genotypic methods based on detection of mutations
conferring drug resistance have been developed and used as
rapid methods for identification of drug resistance.
Resistance to isoniazid (INH) is associated with a variety
of genes, including katG, inhA, ahpC, kasA and ndh [1–4].
Mutation of the katG codon 315 has been shown to be the
most common mechanism of INH resistance [5–7]. Ethiona-
mide (ETH) is one of the most frequently used effective sec-
ond-line drugs. The monooxygenase enzyme encoded by the
ethA gene has recently been identified and found to be capa-
ble of converting ETH to an active form. Alterations in ethA
confer ETH resistance [8,9]. However, there is limited infor-
mation on the occurrence of ethA mutations in ETH-resistant
Mycobacterium tuberculosis clinical isolates. In particular, there
have been no studies on ETH-resistant isolates in Thailand.
This study aims to characterize the type and frequency of
mutations conferring INH and ETH resistance in drug-resis-
tant M. tuberculosis clinical isolates from Thailand.
Overall, 170 isolates (one isolate/patient) comprising 160
INH-resistant and 10 INH-susceptible isolates were ran-
domly selected from the Molecular Mycology and Mycobac-
teriology Laboratory, Drug Resistant Tuberculosis Research
Fund during 2005–2006. Mycobacteria were cultured on
Lo¨wenstein–Jensen medium and incubated at 37C for 3–4
weeks. The susceptibility testing was performed using the
standard disc elution method [10]. All INH-resistant and
ETH-resistant isolates were resistant to ‡1 lg/mL of INH
and ‡5 lg/mL of ETH, respectively.
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Genomic DNA was isolated using the boiling method.
Amplification by PCR was performed according to the stan-
dard protocol described elsewhere. Primer sequences are
listed in Table 1. PCR products were purified from 2.5% aga-
rose gels after electrophoresis and submitted for DNA
sequencing at Macrogen Sequencing Service (Macrogen,
Korea). The PCR primers were also used as sequencing prim-
ers. DNA sequences obtained were compared with the wild-
type sequence of M. tuberculosis H37Rv using Clustal X.
Sequence analysis of 160 INH-resistant isolates revealed
that 129 isolates (80.6%) had mutations in the katG gene.
The predominant amino acid substitution was Ser315Thr,
detected in 128 isolates. Most INH-resistant isolates (91.9%)
and all susceptible isolates possessed a leucine at codon 463.
Mutation at this position, however, is not associated with
INH resistance. Two novel mutations were found:
Trp328Ser and a nonsense mutation Gln352Stop. Analysis of
the inhA gene, including the promoter region, revealed muta-
tions in 22 of the remaining 31 isolates. Nine of the isolates
(5.6%) did not possess mutations in either katG or inhA
genes.
The oxyR–ahpC intergenic region and ndh gene were sub-
sequently analysed in these isolates and the results revealed
a single point mutation in the oxyR–ahpC intergenic region in
four isolates, and in the ndh gene in one isolate. All results
are summarized in Table 2.
Of 24 ETH-resistant MDR-TB isolates, 13 (54.2%) had
mutations associated with ETH resistance in the ethA gene.
Interestingly, the mutations are dispersed along the entire
gene. No particular codon was found to be predominant;
however, amino acid substitutions Leu397Arg and Leu328-
Met were each found in three (12.5%) of the 24 isolates
(Table 2). Six isolates had mutations only in the inhA. How-
ever, these mutations were also detected in ETH-susceptible
isolates.
TABLE 1. Oligonucleotide primers used in this study
Gene Primer [Ref.] Sequence (5¢ ﬁ 3¢)
katG Gfor3 [6] TTTCGGCGCATGGCCATGA
Greva GCTTGTCGCTACCACGGAA
inhA inhA-1 [14] CCTCGCTGCCCAGAAAGGGA
inhA-4a [14] AGCGCCTTGGCCATCGAAGCA
oxyR–ahpC
intergenic
region
AHPC1 [20] CCGCAACGTCGACTGGCTCA
AHPC2a [20] GCGTCGACCTTGGACAGGTC
ndh ndh1F ATGAGTCCCCAGCAAGAACC
ndh1Ra AGCTCAACCCGTGATTGCTC
ndh2F CAGCTGGGTGCGATGGTCA
ndh5ASa [3] ACTGAGTACCTGGCAGGCTG
ethA ethA-1 [14] ATCATCGTCGTCTGACTATGG
ethA-5a [14] ACTACAACCCCTGGGACC
ethA-4 [14] CCTCGACCTTCCCGTGA
ethA-9a [14] CCTCGAGTACGTCAAGAGCAC
ethA-8 [14] GGTGGAACCGGATATGCCTG
ethA-Sua GGATTCTCGGCAAGGGTCTG
aSequences are in the reverse complement orientation relative to the GenBank
sequence (Accession no. NC 000962).
TABLE 2. Distribution of mutations
among 160 INH-resistant and
Mycobacterium tuberculosis isolates Mutated
gene
Type and location of mutations (no.)
MDR-TB
(n = 110)
INH-resistanta
(n = 24)
INH-monoresistantb
(n = 26)
katG S315T (9) S315T (3) S315T/R463L (14)
S315T/R463L (83) S315T/R463L (15) S315T/R463L/
S315N/R463L (1) A424G (1)
W328S/R463L (1) S315T/R463L/
Q352Stop (1) V248I (1)
inhA C()15)T (2) C()15)T (4) C()15)T (7)
C()15)T/G40W (1) T()8)C (1)
C()15)T/I21N (1)
C()15)T/I21V (1)
C()15)T/S94A (1)
S94A (2)
S94W (1)
L11V (1)
OxyR-ahpC G()9)A (1) C()10)T (1)
C()10)A (1) C()10)A (1)
ndh T424I (1)
ethA D49A (1)
T232A (2)
S266R (1)
L328M (1)
L328M/L333R (2)
L397R (3)
D49A/N345K (1)
GT deletion 638–639nt (1)
C deletion 613nt (1)
aResistant to INH and other first-line drugs except rifampicin.
bResistant only to INH.
CMI Research Notes 397
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 389–399
Overall, of the 160 INH-resistant isolates, 156 (97.5%)
had mutations either in the coding regions of three genes
(katG, inhA and ndh) or in two regulatory regions (the pro-
moter of inhA and ahpC). Mutations in the katG gene were
predominant (80.6%), particularly at Ser315Thr (79.4%).
These results are consistent with those from earlier studies
in Thailand [11,12] and other countries [5,13–15]. In con-
trast to the study in 1997 demonstrating that katG gene
mutations in 19 INH-resistant Thai isolates comprised 26%
deletions, 26% insertions and 47% point mutations [16], our
study found only one isolate with a truncated KatG (388
amino acids deletion at C-terminus). Our results support the
hypothesis that the absence of katG gene affects survival of
the katG-deleted strains and that Ser315Thr does not have
any deleterious effect on bacterial fitness. Furthermore, our
results revealed the higher percentage of Ser315Thr in MDR
isolates than in the INH-monoresistant strains (86.4% and
61.5%, respectively; p <0.05). Although amino acid polymor-
phism at codon 463 (Arg or Leu) has not been found to con-
fer INH resistance, it is one of genetic markers used for
classifying M. tuberculosis complex into three genotypic
groups [17]. Most of our isolates (157 of 170) had leucine at
this codon, indicating that they are in genotypic group 1.
Mutations in the inhA gene represent the second most
common resistance mechanism; our results revealed these
mutations in 13.8% of all resistant isolates. Concerning each
resistant group, one observation is that the inhA mutations
represent a higher percentage of the mutations in non-MDR
(20–27%) than in MDR isolates (9%).
These results confirm the different distribution of katG
and inhA mutations among MDR and non-MDR isolates.
The remaining mutations occurred in the oxyR–ahpC inter-
genic region (2.5%) and ndh gene (0.6%). The type and loca-
tion of these mutations were similar to those reported
previously [3,18–20], excepting a mutation of ndh at
Thr424Ile. Four of the isolates (2.5%) showed no mutations
in any of the investigated genes or DNA fragments, indicating
other, unknown mechanisms involved in the resistance phe-
notype.
Point mutations of the ethA associated with ETH resis-
tance were detected in 13 (54.2%) isolates. These mutations
have not been reported in previous studies [8,14]. The ethA
mutations appear to be widely dispersed along the gene,
except for amino acid substitutions at codons 328 and 397
that each made up 12.5% of the mutations in the ETH-resis-
tant MDR-TB isolates.
Concerning a possible correlation between inhA mutation
and ETH resistance, this study clearly demonstrates that
there is no association between inhA mutations and ETH
resistance.
In summary, up to 90% of INH-resistant isolates had
mutations either in katG or inhA. These results are valuable
in confirming the use of these targets for developing rapid
and specific genetic methods to identify INH-resistant
M. tuberculosis in Thailand and worldwide. However, geo-
graphical differences among M. tuberculosis populations should
be taken into consideration.
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